A minimal physiologically based pharmacokinetic model that predicts anti-PEG IgG-mediated clearance of PEGylated drugs in human and mouse

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • McSweeney, M.D.
    • Eshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics
  • Wessler, T.
    • College of Arts and Sciences, Department of Mathematics
  • Price, L.S.L.
    • Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics
  • Ciociola, E.C.
    • Eshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics
  • Herity, L.B.
    • Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics
  • Piscitelli, J.A.
    • Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics
  • Zamboni, W.C.
    • Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics
  • Forest, M.G.
    • College of Arts and Sciences, Department of Mathematics
  • Cao, Y.
    • Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics
  • Lai, S.K.
    • Other Affiliation: Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA
Abstract
  • Circulating antibodies that specifically bind polyethylene glycol (PEG), a polymer routinely used in protein and nanoparticle therapeutics, have been associated with reduced efficacy and increased adverse reactions to some PEGylated therapeutics. In addition to acute induction of anti-PEG antibodies (APA) by PEGylated drugs, typically low but detectable levels of APA are also found in up to 70% of the general population. Despite the broad implications of APA, the dynamics of APA-mediated clearance of PEGylated drugs, and why many patients continue to respond to PEGylated drugs despite the presence of pre-existing APA, remains not well understood. Here, we developed a minimal physiologically based pharmacokinetic (mPBPK) model that incorporates various properties of APA and PEGylated drugs. Our mPBPK model reproduced clinical PK data of APA-mediated accelerated blood clearance of pegloticase, as well as APA-dependent elimination of PEGyated liposomes in mice. Our model predicts that the prolonged circulation of PEGylated drugs will be compromised only at APA concentrations greater than ~500 ng/mL, providing a quantitative explanation to why the effects of APA on PEGylated treatments appear to be limited in most patients. This mPBPK model is readily adaptable to other PEGylated drugs and particles to predict the precise levels of APA that could render them ineffective, providing a powerful tool to support the development and interpretation of preclinical and clinical studies of various PEGylated therapeutics.
Date of publication
Keyword
DOI
Identifier
Resource type
  • Article
Journal title
  • Journal of Controlled Release
Journal volume
  • 284
Page start
  • 171
Page end
  • 178
Version
  • Postprint
Funder
  • National Institute of Biomedical Imaging and Bioengineering
  • National Institute of General Medical Sciences
  • National Heart Lung and Blood Institute
  • National Cancer Institute
  • David and Lucile Packard Foundation
  • Directorate for Mathematical & Physical Sciences
ISSN
  • 0168-3659
  • 1873-4995
Publisher
  • Elsevier

Relations

Parents:

This work has no parents.

Items

Thumbnail Title Date Uploaded Visibility Actions
file details nihms978210.pdf 2024-06-14 Public Download